Lonza Group AG (LZAGY)
| Market Cap | 50.81B |
| Revenue (ttm) | 8.92B |
| Net Income (ttm) | 921.69M |
| Shares Out | n/a |
| EPS (ttm) | 13.04 |
| PE Ratio | 55.12 |
| Forward PE | 31.93 |
| Dividend | 0.30 (0.42%) |
| Ex-Dividend Date | May 14, 2025 |
| Volume | 385 |
| Average Volume | 72,673 |
| Open | 72.27 |
| Previous Close | 70.26 |
| Day's Range | 71.67 - 72.52 |
| 52-Week Range | 55.57 - 73.29 |
| Beta | 0.81 |
| RSI | 56.60 |
| Earnings Date | Jul 23, 2025 |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substanc... [Read more]
Financial Performance
In 2024, Lonza Group AG's revenue was 6.57 billion, a decrease of -2.13% compared to the previous year's 6.72 billion. Earnings were 636.00 million, a decrease of -2.75%.
Financial numbers in CHF Financial StatementsNews
Lonza Group AG 2025 Q2 - Results - Earnings Call Presentation
Lonza Group AG (LZAGY) Q2 2025 Earnings Call Transcript
Markets Today: FTSE 100 Hits Record High Amid European Market Surge, Tesla & Alphabet Earnings Ahead
European stocks rallied over 1% on Wednesday, driven by hopes of a US-EU trade deal. The STOXX 600 index climbed 1.1%, and the UK’s FTSE 100 hit a record high. Carmaker shares surged, with Temenos jum...
Lonza Group AG reports 1H results
Lonza reports CHF 3.6B in 1H sales (+19% CER) with a 29.6% margin. FY 2025 CDMO sales growth upgraded to 20-21%.
Lonza Group: Expected Growth And Macroeconomic Uncertainty - Is It Undervalued?
Lonza Group AG (LZAGY) Q1 2025 Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q1 2025 Earnings Conference Call May 9, 2025 9:00 AM ETCompany ParticipantsPhilippe Deecke - Chief Financial OfficerConference...
Lonza: Well Equipped In The U.S., Buy Confirmed
Lonza is poised for growth amid margin recovery, onshoring opportunities, and strong profit projections. Read more on LZAGY stock here.
Lonza Group Appears To Be Fully Valued At This Time (Rating Downgrade)
Lonza Group AG plans to focus on CDMO segment, despite revenue decrease. Click here to read more on the analysis of LZAGY stock.
Lonza Posts Lower Sales, Earnings But Expects Capsules Business Rebound This Year
Lonza Sees Accelerating Sales Growth in Final Quarter
The Swiss life-sciences company said it expected accelerated sales growth in the fourth quarter on the back of the timing of product releases and the ramp-up of its new acquired manufacturing facility...
Acumen Pharmaceuticals extends collaboration with Lonza
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer's Disease
Agreement builds upon a successful collaboration supporting the manufacture of sabirnetug (ACU193) drug substance (DS) for clinical studies in Alzheimer's disease Extension to provide drug product (DP...
Lonza Group AG (LZAGY) Q2 2024 Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q2 2024 Earnings Conference Call July 25, 2024 7:00 AM ET Company Participants Wolfgang Wienand - Chief Executive Officer Philippe Deecke - Chief Financial Officer Confere...
LZAGY, DSDVY: Investment Opportunities Outside of the U.S.
U.S. equity markets have benefitted from a perceived quality advantage over Europe, though it's uncertain when outperformance will end, notes Bryan Lee. He discusses finding investment opportunities o...
Lonza Group AG (LZAGY) Q1 2024 Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Albert Baehny - Interim Chief Executive Officer & Chairman of the Board of Directors Philippe...
Lonza: Acceleration In Mid-Term Sales Growth
Reflecting Lonza's Vacaville acquisition, we increased our sales and EBITDA expectations. The company has an ongoing buyback and a progressive dividend per share. We positively view the new CEO appoin...
Lonza: Excellent Growth Projections Will Sharply Increase Free Cash Flow
Lonza Group aims to increase revenue by double digits by 2028 through aggressive expansion in the CDMO space. Lonza expects to increase its EBITDA margin to 32%-34% by 2028 and maintain a low debt rat...
Lonza Group AG (LZAGY) Q4 2023 Earnings Call Transcript
Lonza Group AG (LZAGY) Q4 2023 Earnings Call Transcript
Lonza chairman to step down, drugmaker confirms targets, shares soar
Lonza said on Friday Chairman Albert Baehny will step down in May after six years in the job, in a second senior management reshuffle in recent months as the Swiss contract drug manufacturer grapples ...
Lonza: The Day Has Come, And We Lower Our Expectation
Here at the Lab, post Capital Market Day, we are in a show-me-story scenario. Moderna contract termination is a positive short-term catalyst; however, it is an adverse concern over the biotech sector'...
Lonza Group: Downside Scenario Already Priced In
Lonza's CEO departure raises questions about business continuity, but we believe the stock price already reflects the worst-case scenario. Lower CAPEX and an ongoing buyback program (with potential M&...
Lonza CEO departure prompts concern over earnings prospects
Contract drug manufacturer Lonza said on Monday Chief Executive Pierre-Alain Ruffieux will leave the Swiss company by mutual agreement at the end of the month, weighing on investor confidence about th...
Biopharma Bounce-Back: From Policy Pains To Profitable Plains
The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail ...
Lonza Group AG (LZAGY) Q2 2023 Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q2 2023 Earnings Conference Call July 21, 2023 8:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Richard Vosse...
Lonza: Our Thoughts Pre Capital Market Day, Buy Confirmed
Despite a challenging economic environment, Lonza announced an increase in CAPEX, positioning itself to capture long-term growth opportunities in the healthcare sector. We positively favor Lonza's cap...